Anteotech Ltd
ASX:ADO
Anteotech Ltd
AnteoTech Ltd. is a global nano-technology company, which develops, manufactures, and distributes products for the life sciences, clinical diagnostics and bio-separations markets. The company is headquartered in Eight Mile Plains, Queensland. The company went IPO on 2000-04-11. The firm is focused on the development and commercialization of its intellectual property of specialized surfaces used in the life sciences, diagnostics, energy and medical devices markets. The firm's products include AnteoCoat, AnteoBind and AnteoRelease, which are used in the energy, diagnostic and medical device markets. The firm's AnteoBind is an aqueous nanosized molecular glue (polymeric metal ions) used in a single-step process to facilitate multivalent coordination to bind carbohydrate polymers, antibodies, and proteins to synthetic substrates in assay development. The firm is also developing, SARS-CoV-2 Ag rapid test, which is a single-use, disposable, lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal specimens collected from individuals who are suspected of COVID-19 infection.
AnteoTech Ltd. is a global nano-technology company, which develops, manufactures, and distributes products for the life sciences, clinical diagnostics and bio-separations markets. The company is headquartered in Eight Mile Plains, Queensland. The company went IPO on 2000-04-11. The firm is focused on the development and commercialization of its intellectual property of specialized surfaces used in the life sciences, diagnostics, energy and medical devices markets. The firm's products include AnteoCoat, AnteoBind and AnteoRelease, which are used in the energy, diagnostic and medical device markets. The firm's AnteoBind is an aqueous nanosized molecular glue (polymeric metal ions) used in a single-step process to facilitate multivalent coordination to bind carbohydrate polymers, antibodies, and proteins to synthetic substrates in assay development. The firm is also developing, SARS-CoV-2 Ag rapid test, which is a single-use, disposable, lateral flow test for the qualitative detection of SARS-CoV-2 nucleocapsid antigen in nasopharyngeal specimens collected from individuals who are suspected of COVID-19 infection.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
